Scientists attack 'Chemo-Resistant' breast cancer with new drug cocktail
NCT ID NCT05660083
Summary
This study is testing a new three-drug combination for people with a rare and aggressive type of breast cancer called metaplastic breast cancer (MpBC), which has stopped responding to standard treatments. The goal is to see if adding two new drugs (alpelisib and L-NMMA) to a standard chemotherapy (nab-paclitaxel) can help control the cancer better. The trial will enroll about 36 adults with advanced, HER2-negative MpBC to test the safety and effectiveness of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
National Institute of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.